drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
A human IgG1κ monoclonal antibody administered intravenously with FcRn-enhanced half-life that binds the “a” determinant on hepatitis B surface antigen (HBsAg). It neutralizes HBV virions and subviral particles, forms immune complexes to accelerate antigen clearance, engages Fcγ receptor–mediated effector functions (e.g., ADCC, phagocytosis), and lowers circulating HBsAg to mitigate T-cell exhaustion and potentially restore adaptive immune responses.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Monoclonal
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Human IgG1κ monoclonal antibody with FcRn-enhanced half-life that binds the “a” determinant of hepatitis B surface antigen (HBsAg). It neutralizes HBV virions and subviral particles and forms immune complexes that accelerate antigen clearance, while engaging Fcγ receptors to drive ADCC and phagocytosis. By lowering circulating HBsAg, it may reduce T-cell exhaustion and help restore HBV-specific adaptive immune responses.
drug_name
HepB mAb19
nct_id_drug_ref
NCT06668727